Cited by 112Schizophrenia research and treatmentMedication Adherence and CompliancePsychotherapy Techniques and Applications

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies

Open access

Czobor, Pál, Van Dorn, Richard A., Citrome, Leslie, Kahn, Rene S., Fleischhacker, W. Wolfgang, Volavka, Jan·2015·European Neuropsychopharmacology

DOI 10.1016/j.euroneuro.2015.04.003PMC PMC4860611

Open this paper in CoChat — free account

Abstract

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) obtained a sample of 1493 chronic schizophrenia patients. The European First Episode Schizophrenia Trial (EUFEST) studied a sample of 498 patients. We have combined these two samples to study the predictors and correlates of adherence to treatment. Here we report on adherence to pharmacological treatment at the six and twelve month assessments of these trials with a combined subsample of 1154 schizophrenia patients. Individual patients׳ data were used for analyses. We used logistic regression to examine the effects of substance use, akathisia, parkinsonism, dyskinesia, hostility, and insight on pharmacological adherence. The results showed that reduced adherence to pharmacological treatment was associated with substance use (p=0.0003), higher levels of hostility (p=0.0002), and impaired insight (p<0.0001). Furthermore, poor adherence to study medication was associated with earlier discontinuation in the combined data. The clinical implications of the results point to the importance of routine assessments and interventions to address patients׳ insight and comorbid substance use and the establishment of therapeutic alliance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2015.04.003

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Untitled work
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Untitled work
(1998) · PubMed · Cited by 10,216
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
Flexible Imputation of Missing Data
van Buuren, S. (2012) · doi:10.1201/b11826 · Cited by 2,022
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 3×
“The other eight studies demonstrated little or no association (Lacro et al., 2002).”
BackgroundResult

Show all 49 references

Research works printed but not linked: 1

Velligan, 2009, The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J. Clin. Psychiatry, 70, S1

Sorted by citations

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients
García, S., Martínez‐Cengotitabengoa, M., López-Zurbano, S., Zorrilla, E. P., López‐Mahía, P., Vieta, E., & González-Pinto, A. M. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000523 · Cited by 363
Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments
Lysaker, P. H., Pattison, M. L., Leonhardt, B. L., Phelps, S., & Vohs, J. L. (2018) · World Psychiatry · doi:10.1002/wps.20508 · Cited by 247
Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214
Insight and medication adherence in schizophrenia: An analysis of the CATIE trial
Kim, J., Ozzoude, M., Nakajima, S., Shah, P., Caravaggio, F., Iwata, Y., Luca, V. D., Graff‐Guerrero, A., & Gerretsen, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.011 · Cited by 144
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Parellada, E., & Bioque, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0350-7 · Cited by 90
Is It Possible to Predict the Future in First-Episode Psychosis?
Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T. J. S., Rikandi, E., Lindgren, M., Kieseppä, T., & Raij, T. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00580 · Cited by 96
How should a virtual agent present psychoeducation? Influence of verbal and textual presentation on adherence
Tielman, M. L., Neerincx, M. A., van Meggelen, M., Franken, I., & Brinkman, W.-P. (2018) · Technology and Health Care · doi:10.3233/thc-170899 · Cited by 63
“therapist alliance is related to adherence [32,33].”
Background
Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria
Owie, G. O., Olotu, S. O., & James, B. O. (2018) · Trends in Psychiatry and Psychotherapy · doi:10.1590/2237-6089-2017-0077 · Cited by 55
Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis
Zisman‐Ilani, Y., Shern, D. L., Deegan, P. E., Kreyenbuhl, J. A., Dixon, L. B., Drake, R. E., Torrey, W. C., Mishra, M. K., Gorbenko, K. O., & Elwyn, G. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1707-x · Cited by 47
Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment
Faden, J., & Citrome, L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543409 · Cited by 44
Self-citation
Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness
Alipour, A., Gabrielson, S. W., & Patel, P. B. (2020) · Pharmacy · doi:10.3390/pharmacy8020103 · Cited by 47
Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics
Misdrahi, D., Tessier, A., Daubigney, A., Meissner, W. G., Schürhoff, F., Boyer, L., Godin, O., Bulzacka, E., Aouizerate, B., Andrianarisoa, M., et al. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12246 · Cited by 43
Decriminalizing mental illness: specialized policing responses
Dempsey, C., Quanbeck, C., Bush, C., & Kruger, K. (2019) · CNS Spectrums · doi:10.1017/s1092852919001640 · Cited by 52
A qualitative study of medication adherence amongst people with schizophrenia
Clifford, L., Crabb, S., Turnbull, D. A., Hahn, L. A., & Galletly, C. A. (2020) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2020.06.002 · Cited by 39
Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region
Tang, C. T., Chua, E. C., Chew, Q. H., He, Y., Si, T., Chiu, H. F. K., Xiang, Y., Kato, T. A., Kanba, S., Shinfuku, N., et al. (2020) · Asia-Pacific Psychiatry · doi:10.1111/appy.12393 · Cited by 39
An update on clinical insight, cognitive insight, and introspective accuracy in schizophrenia-spectrum disorders: symptoms, cognition, and treatment
Mervis, J., Vohs, J. L., & Lysaker, P. H. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2049757 · Cited by 37
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil
Citrome, L. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121809 · Cited by 37
Self-citation
Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome
Olagunju, A. T., Clark, S. R., & Baune, B. T. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419837358 · Cited by 33
Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study
Krzystanek, M., Krysta, K., & Skałacka, K. (2017) · Journal of Technology in Behavioral Science · doi:10.1007/s41347-017-0016-4 · Cited by 31
The impact of self-stigmatization on medication attitude in schizophrenia patients
Feldhaus, T., Falke, S., von Gruchalla, L., Maisch, B., Uhlmann, C., Bock, E., & Lencer, R. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.01.012 · Cited by 30
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study
Fortea, A., Ilzarbe, D., Espinosa, L., Solerdelcoll, M., de Castro, C., Oriolo, G., Sugranyes, G., & Baeza, I. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0096 · Cited by 31
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies
Volavka, J., Dorn, R. A. V., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Czobor, P. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.10.003 · Cited by 30
Self-citation
Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders
Leijala, J., Kampman, O., Suvisaari, J., & Eskelinen, S. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03037-0 · Cited by 35
Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine
Citrome, L., & Volavka, J. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000275 · Cited by 28
Self-citation
Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment
Curto, M., Fazio, F., Ulivieri, M., Navari, S., Lionetto, L., & Baldessarini, R. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882996 · Cited by 29
A longitudinal analysis of the overlap between violence and victimization among adults with mental illnesses
Johnson, K. L., Desmarais, S. L., Tueller, S., Grimm, K. J., Swartz, M. S., & Dorn, R. A. V. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.039 · Cited by 28
Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study
Rezansoff, S. N., Moniruzzaman, A., Fazel, S., Procyshyn, R. M., & Somers, J. M. (2016) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1259-7 · Cited by 26
Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits
Joshi, K., Lafeuille, M., Kamstra, R. L., Tiggelaar, S., Lefèbvre, P., Kim, E., Yue, Y. G., & Tandon, N. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0043 · Cited by 25
Clozapine augmentation strategies
Roerig, J. L. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.336 · Cited by 28
Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia
Kim, J., Plitman, E., Nakajima, S., Alshehri, Y., Iwata, Y., Chung, J. K., Caravaggio, F., Menon, M., Blumberger, D. M., Pollock, B. G., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2019.06.007 · Cited by 21
The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations
Arango, C., Buitelaar, J. K., Correll, C. U., Díaz‐Caneja, C. M., Figueira, M. L., Fleischhacker, W. W., Marcotulli, D., Parellada, M., & Vitiello, B. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.04.005 · Cited by 25
Self-citation
Adherence, insight and disability in paranoid schizophrenia
García‐Cabeza, I., Díaz‐Caneja, C. M., Bruna, M. M. O., & Portugal, E. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.021 · Cited by 24
How long should antipsychotic treatment be continued after a single episode of schizophrenia?
Emsley, R. A., Kilian, S., & Phahladira, L. S. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000249 · Cited by 20
Effect of a Telephone Intervention Upon Self-Reported Medication Adherence and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs)
Beebe, L. H., Smith, K., & Phillips, C. (2016) · Issues in Mental Health Nursing · doi:10.1080/01612840.2016.1214855 · Cited by 20
Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs – A study based on blood sample analyses from 24,239 patients
Smith, R. L., Tveito, M., Kyllesø, L., Jukić, M. M., Ingelman‐Sundberg, M., Andreassen, O. A., & Molden, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.06.007 · Cited by 20
Effect of a Telephone Intervention on Measures of Psychiatric and Nonpsychiatric Medication Adherence in Outpatients With Schizophrenia Spectrum Disorders
Beebe, L. H., Smith, K., & Phillips, C. (2017) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20170119-04 · Cited by 19
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
Baeza, I., Fortea, A., Ilzarbe, D., & Sugranyes, G. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00558-x · Cited by 18
Treatment-resistant schizophrenia: challenges and implications for clinical practice.
Šagud, M. (2015) · PubMed · Cited by 18
Interventions to improve medication adherence in mental health: the update of a systematic review of cost-effectiveness
García‐Pérez, L., Linertová, R., Serrano-Pérez, P., Trujillo‐Martín, M. M., Rodríguez‐Rodríguez, L., Valcárcel‐Nazco, C., & del Pino‐Sedeño, T. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1782434 · Cited by 20
Predicting factors for non-suicidal self-injury in patients with schizophrenia spectrum disorders and the role of substance use
Güney, E., Alnıak, İ., & Erkıran, M. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102068 · Cited by 17
Medication nonadherence among South American patients with schizophrenia
Caqueo‐Urízar, A., Alfonso Urzúa, M., Fond, G. B., & Boyer, L. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s144961 · Cited by 16
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs , a randomized, open‐label study
Ishigooka, J., Nakagome, K., Ohmori, T., Iwata, N., Inada, K., Iga, J., Kishi, T., Fujita, K., Kikuchi, Y. S., Shichijo, T., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13304 · Cited by 15
Poor Insight in Schizophrenia Patients in China: a Meta-Analysis of Observational Studies
Li, W., Zhang, H.-H., Wang, Y., Zhang, L., Ungvari, G. S., Cheung, T. C. C., & Xiang, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09786-7 · Cited by 15
Descriptions and Correlates of Medication Adherence, Attitudes, and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs)
Beebe, L. H., Smith, K., & Phillips, C. (2016) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2016.01.010 · Cited by 15
The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia
Lim, M., Li, Z., Xie, H., Tan, B., & Lee, J. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001449 · Cited by 14
The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia
Davidson, M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.3/mdavidson · Cited by 15
The Psychosocial Impact of Insight Paradox and Internalized Stigma in Chronic Psychotic Disorders
García, J. J. M., Hodann-Caudevilla, R. M., Castaño, A. G., Garrido, S. A., Tischhauser, R. D., Rada, Á. P., & Salom, R. (2025) · Behavioral Sciences · doi:10.3390/bs15040410 · Cited by 16
A multi-dimensional approach to the relationship between insight and aggressiveness in schizophrenia: Findings from the FACE-SZ cohort
Schandrin, A., Norton, J. L., Raffard, S., Aouizerate, B., Berna, F. S., Brunel, L., Chéreau, I., d’Amato, T., Denizot, H., Dubertret, C., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.07.029 · Cited by 13
Understanding Helpful Nursing Care From the Perspective of Mental Health Inpatients With a Dual Diagnosis: A Qualitative Descriptive Study
Brahim, L. O., Hanganu, C., & Gros, C. P. (2019) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390319878773 · Cited by 12
Relationships between neuropsychological performance, insight, medication adherence, and social metacognition in schizophrenia
Roux, P., Faivre, N., Urbach, M., Aouizerate, B., Brunel, L., Capdevielle, D., Chéreau, I., Dubertret, C., Dubreucq, J., Fond, G. B., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2022.12.037 · Cited by 13
The contribution of alexithymia, childhood maltreatment, impulsivity, C-reactive protein, lipid profile, and thyroid hormones to aggression and psychological distress (depression and anxiety) in schizophrenia
Khosravani, V., Sharifibastan, F., Aghaeimazraji, M., Berk, M., & Ardestani, S. M. S. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107087 · Cited by 12
Self-reported treatment adherence among psychiatric in- and outpatients
Karpov, B., Joffe, G., Aaltonen, K. I., Oksanen, J., Suominen, K. H., Melartin, T. K., Baryshnikov, I., Koivisto, M., Heikkinen, M. E., & Isometsä, E. T. (2018) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2018.1538387 · Cited by 12
Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence
Davidson, M., & Carpenter, W. T. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad145 · Cited by 12
Predictors of medication adherence in a large 1-year prospective cohort of individuals with schizophrenia: insights from the multicentric FACE-SZ dataset
Misdrahi, D., Dupuy, M., Dansou, Y., Boyer, L., Berna, F. S., Capdevielle, D., Chéreau, I., Coulon, N., d’Amato, T., Dubertret, C., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02640-x · Cited by 11
Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
Kim, J., Pae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.4.600 · Cited by 11
Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics
Cuevas, C. D. L., & de León, J. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s242693 · Cited by 13
Hospital and patient factors influencing the health status among patients with schizophrenia, thirty days after hospital discharge: multi-level analysis
Smithnaraseth, A., Seeherunwong, A., Panitrat, R., & Tipayamongkholgul, M. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-03001-4 · Cited by 10
Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia
Kim, J., Song, J., Kambari, Y., Plitman, E., Shah, P., Iwata, Y., Caravaggio, F., Brown, E. E., Nakajima, S., Chakravarty, M. M., et al. (2023) · Schizophrenia · doi:10.1038/s41537-023-00347-y · Cited by 9
Improving Adherence in Hospitalized Patients Diagnosed With Schizophrenia: An Integrative One-on-One Intervention
Dahan, S., Behrbalk, P., Stolovy, T., & Greenberger, C. (2016) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2016.03.002 · Cited by 9
The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study
Aguglia, A., Fusar‐Poli, L., Amerio, A., Placenti, V., Concerto, C., Martinotti, G., Carrà, G., Bartoli, F., D’Agostino, A., Serafini, G., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.784366 · Cited by 8
Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients
Iasevoli, F., Fagiolini, A. M., Formato, M. V., Prinzivalli, E., Giordano, S., Balletta, R., Luca, V. D., & de Bartolomeis, A. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.01.015 · Cited by 9
Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward
Brasso, C., Cisotto, M., Ghirardini, C., Pennazio, F., Villari, V., & Rocca, P. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114214 · Cited by 7
Insight's level in borderline personality disorder, questioning consciousness
Martin, S. S., Graziani, P., & Del-Monte, J. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100045 · Cited by 7
Poor insight and self-disorders in schizophrenia: an empirical study
Nilsson, L. S., Nordgaard, J., Henriksen, M. G., Parnas, J., & Rasmussen, A. R. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02035-7 · Cited by 6
The clinician–patient working alliance: is it a significant predictor of psychiatric medication adherence in a sample of recently released parolees?
Calhoun, S. (2018) · Journal of Forensic Psychiatry and Psychology · doi:10.1080/14789949.2018.1477976 · Cited by 6
Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia
Daniell, K., Kim, J., Iwata, Y., Caravaggio, F., Brown, E. E., Remington, G. J., Agid, O., Graff‐Guerrero, A., & Gerretsen, P. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.016 · Cited by 6
Schizophrene Psychosen
Falkai, P., Schennach, R., Lincoln, T. M., Schaub, A., & Hasan, A. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_64-1 · Cited by 9
Psychopathological networks in psychosis: Changes over time and clinical relevance. A long-term cohort study of first-episode psychosis
Gil‐Berrozpe, G. J., Peralta, V., Sánchez-Torres, A. M., Moreno-Izco, L., de Jalón, E. G., Peralta, D., Janda, L., Cuesta, M. J., Ballesteros, A., Hernández, R., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2022.12.046 · Cited by 6
Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data
Stockbridge, E. L., Webb, N. J., Dhakal, E., Garg, M., Loethen, A. D., Miller, T. L., & Nandy, K. (2021) · BMC Health Services Research · doi:10.1186/s12913-020-06045-0 · Cited by 8
Medication non-adherence in re-admitted patients at a psychiatry hospital: A qualitative study
Zwide, G. E., Dewet, Z. T., & Sokudela, F. B. (2025) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v31i0.2345 · Cited by 5
A Review of Pharmacokinetic and Pharmacodynamic Properties of Quetiapine IR and XR: Insights and Clinical Practice Implications
Joshi, K., Rao, S., & Mehta, S. C. (2025) · Cureus · doi:10.7759/cureus.86258 · Cited by 5
Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial
Stabell, L. A., Johnsen, E., Kroken, R. A., Løberg, E., Blindheim, A. A., Joa, I., Reitan, S. K., Rettenbacher, M. A., Munk‐Jørgensen, P., & Gjestad, R. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04981-9 · Cited by 5
Clinical and psychological correlates of insight dimensions in patients with early psychosis
Kam, T. K., Lui, T. T., Lau, F. C., Chan, S. K. W., Lee, E. H. M., Hui, C. L. M., Suen, Y. N., Lui, S. S. Y., Chen, E. Y. H., & Chang, W. C. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13191 · Cited by 4
Introspective accuracy for substance use across a year of treatment for first episode psychosis
Mervis, J., Fischer, J., Cooper, S. E., Deckert, A. C., Lysaker, P. H., MacDonald, A. W., & Meyer-Kalos, P. (2021) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2021.100200 · Cited by 4
Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia: Practical Considerations
Kverno, K. S., & Rozenberg, I. (2021) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20210611-04 · Cited by 4
Investing in a Research Workforce With Personal Experience of Serious Mental Illness
Kimhy, D., Jones, N., & Dixon, L. B. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2026 · Cited by 4
Correlation Between Efficacy of Treatment with Anti-psychotics and Adherence in Schizophrenic Patients: A Cross-sectional Study in Saudi Arabia
Shilbayeh, S. A. R., Aldosari, F. N., Al-Sahabi, W., Al-Saif, M., Al-Najjar, A. H., & Albogami, N. (2023) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.57.3.111 · Cited by 4
Impaired insight in schizophrenia is associated with higher frontoparietal cerebral blood flow: an arterial spin labeling study
Song, J., Carmona-Torres, E., Kambari, Y., Chavez, S., Ueno, F., Koizum, T., Amaev, A., Abdolizadeh, A., Luca, V. D., Blumberger, D. M., et al. (2025) · Schizophrenia · doi:10.1038/s41537-024-00536-3 · Cited by 7
Effect of a Telephone Intervention upon Medication Adherence and Related Outcomes in Outpatients with Schizophrenia Spectrum Disorders (SSDs)
Beebe, L. H. (2017) · Medical & Clinical Reviews · doi:10.21767/2471-299x.1000048 · Cited by 3
Schizophrene Psychosen
Falkai, P., Schennach, R., Lincoln, T. M., Schaub, A., & Hasan, A. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_64 · Cited by 3
Adherence to Pharmacological Treatment Among Patients with Schizophrenia
Abdulkareem, M., & Mahmood, H. (2022) · Iraqi National Journal of Medicine · doi:10.37319/iqnjm.4.1.4 · Cited by 5
Recovery-Oriented Psychopharmacological Interventions in Schizophrenia
Mallet, J., Strat, Y. L., Dubertret, C., & Gorwood, P. A. P. M. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_9 · Cited by 3
Adherencia a la medicación antipsicótica en pacientes indígenas con esquizofrenia
Caqueo‐Urízar, A., Escuela de Psicología y Filosofía, U. D. T., Alfonso Urzúa, M., Miranda‐Castillo, C., Irarrázaval, M., Escuela de Psicología, U. C. D. N., de Sociología, P. U. C. D. C. I., & Instituto Milenio para la Investigación en Depresión y Personalidad, S. (2016) · Salud Mental · doi:10.17711/sm.0185-3325.2016.035 · Cited by 3
The Challenge of Nonadherence in Schizophrenia
Lawrence, R. E., & Dixon, L. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-12665-0_4 · Cited by 3
Early Clinical Symptom Patterns Predict the Subsequent Treatment Response of Patients with Acute Schizophrenia
Liu, Z., Chen, W., Wang, X. Q., Huang, J., Gou, M., Han, H., Wang, J. P., Wang, D.-H., Chen, S., Xie, T., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag009 · Cited by 2
Suicidal risk in patients with aggression in schizophrenia: a systematic review
Bravve, L. V., Kaydan, M. A., & Kostyuk, G. P. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1560699 · Cited by 2
Long-acting Injectable Antipsychotics and Stigma: Some Considerations and Future Perspectives
Natale, A., Fusar‐Poli, L., Amerio, A., Escelsior, A., Serafini, G., Aguglia, E., Amore, M., & Aguglia, A. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230406102039 · Cited by 2
Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan
Kishi, T., Yoshimura, R., Matsuda, Y., Sakuma, K., & Iwata, N. (2020) · Pharmacopsychiatry · doi:10.1055/a-1096-1266 · Cited by 2
What Do Patients Want? Patient Satisfaction and Treatment Engagement
Webb, A. E., & Gearing, R. E. (2020) · doi:10.1002/9781119129530.ch2 · Cited by 2
Pseudo-Resistant Schizophrenia: Non-Adherence to Treatment
Kim, H., & Lee, S. J. (2020) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2020.23.2.51 · Cited by 1
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis
Alisauskiene, R., Johnsen, E., Gjestad, R., Kroken, R. A., Jørgensen, H. A., & Løberg, E. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1958858 · Cited by 1
Effect of self-stigma on personal recovery: sex differences in people with psychotic spectrum disorders
Leon-Morales, D., Navarro, J. B., Lamarca, M., González‐Higueras, F., Torres, P., Cid, J., Capell, E. F., Birulés, I., Ochoa, S., Vidal, C., et al. (2025) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2025.1655885 · Cited by 1
The Immediate and Sustained Effects of Multi-Session Biparietal Transcranial Direct Current Stimulation on Insight in Schizophrenia
Song, J., Kim, J., Carmona-Torres, E., Kambari, Y., Ueno, F., Koizumi, T., Iwata, Y., Amaev, A., Luca, V. D., Blumberger, D. M., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag022 · Cited by 1
Metacognitive Abilities within Personal Narratives of Inpatients with Schizophrenia: Associations with Clinical Insight and Drug Compliance
Hussein, F., Mohamed, H. S. I., & Eweida, R. S. (2019) · doi:10.7176/jep/10-1-13 · Cited by 1
Improving Treatment Adherence in Schizophrenia
El-Mallakh, P. L., & Findlay, L. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0074-9 · Cited by 1
Progress in Schizophrenia Research and Treatment
(2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18310 · Cited by 1
Psychopharmacology of Violent Behavior Among People with Severe Mental Disorders
Citrome, L., & Volavka, J. (2019) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-33188-7_14
Self-citation
Определение адаптационных ресурсов в процессе реабилитации больных шизофренией с акатизией на фоне антипсихотической терапии
Александровна, Г. А. (2021) · Сибирский вестник психиатрии и наркологии · doi:10.26617/1810-3111-2021-1(110)-13-18
Nonadherence and Mental Health Treatment in Homeless Populations
Hargrave, R., & Noufi, P. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-70135-2_11

Authors: Czobor, P., Van Dorn, R. A., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Volavka, J.
Affiliations: Semmelweis University (HU)
New York Medical College (US)
Innsbruck Medical University (AT)
New York University (US)
Corresponding author: Czobor, Pál
ORCID: Czobor, Pál
Citrome, Leslie
Volavka, Jan
Venue: European Neuropsychopharmacology
Publisher: Elsevier BV
Published: 2015-08
Volume: 25
Issue: 8
Pages: 1158-1166
ISSN: 0924-977X (ISSN-L)
DOI: 10.1016/j.euroneuro.2015.04.003
PMC: PMC4860611
OpenAlex: W2125320544
Cited by: 112
References: 49
Citations by year: 2026: 7 · 2025: 9 · 2024: 2 · 2023: 10 · 2022: 6 · 2021: 16 · 2020: 16 · 2019: 11 · 2018: 13 · 2017: 8 · 2016: 11 · 2015: 3
FWCI: 1.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Semmelweis University Repository (Semmelweis University) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: Bristol-Myers Squibb
National Institute of Mental Health (R01MH093426)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords: medication adherence, schizophrenia, antipsychotic drugs, substance use, hostility, insight, akathisia, parkinsonism, dyskinesia, drug discontinuation, therapeutic relationship, predictors of adherence
MeSH terms: Assessment of Medication Adherence, Humans, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Randomized Controlled Trials as Topic, Drug Monitoring, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks